Annotation Detail

Information
Associated Genes
RET
Associated Variants
RET UNKNOWN
RET FUSION
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
We aimed to assess the efficacy and safety of vandetanib in patients with advanced RET-rearranged NSCLC. In this open-label, multicentre, phase 2 trial (LURET), patients with advanced RET-rearranged NSCLC continuously received 300 mg of oral vandetanib daily. 1536 patients with EGFR mutation-negative NSCLC were screened,, 34 were RET-positive (2%), 19 were enrolled and 17 patients were eligible for primary analysis. 9 patients (53%) achieved and objective response, in the intention to treat population of 19 patients, 9 patients (47% achieved an OR. At data cutoff, median PFS was 4,7 months. The results define RET rearrangement as a new molecular subgroup of NSCLC suitable for targeted therapy.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/4849
Gene URL
https://civic.genome.wustl.edu/links/genes/42
Variant URL
https://civic.genome.wustl.edu/links/variants/1687
Rating
3
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Supports
Drug
Vandetanib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
27825616
Drugs
Drug NameSensitivitySupported
VandetanibSensitivitytrue